House of Representatives

More documents

Recommendations

Info

18 HOUSE OF REPRESENTATIVES Thursday, 1 December 2016 of competition in telecommunications in the past 20 years, these rules under part XIB are no longer necessary or appropriate. Following the proposed amendments, any misuse of market power in the telecommunications sector will be managed by the same general competition laws applying to other sectors of the economy, and which will be strengthened by the enhancements being made to section 46. The Australian Competition and Consumer Commission supports these amendments and retains other extensive powers to deal with other competition concerns in telecommunications. Full details of the measure are contained in the explanatory memorandum. I commend the bill to the House. Debate adjourned. Therapeutic Goods Amendment (2016 Measures No.1) Bill 2016 First Reading Bill and explanatory memorandum presented by Ms Ley. Bill read a first time. Second Reading Ms LEY (Farrer—Minister for Sport and Minister for Health and Aged Care) (10:54): I move: That this bill be now read a second time. I am pleased to introduce the Therapeutic Goods Amendment (2016 Measures No.1) Bill 2016, which amends the Therapeutic Goods Act 1989. A number of the measures in this bill support the recommendations made by the Expert Panel Review of Medicines and Medical Devices Regulation about improving key aspects of the regulatory scheme for therapeutic goods. The reforms reflect extensive consultation undertaken by an expert panel led by Emeritus Professor Lloyd Sansom AO, a distinguished educator, researcher and policy adviser in the health and pharmaceutical sectors. Professor Sansom was assisted by Mr Will Delaat AM and Professor John Horvath AO. The review found that the Therapeutic Goods Administration is well respected internationally and benchmarks well against overseas regulators. However, it also identified areas for improvement, particularly in relation to providing industry with more flexible and timely pathways to market; enabling patients to access new medicines and medical devices faster; increasing collaboration with overseas counterparts to minimise regulatory burden; and enhancing post-market monitoring of the safety of products. The purpose of this bill is to make a number of such changes that will enable members of the public to have access to medicines and medical devices more quickly, while continuing to maintain high standards of safety and efficacy which the public expects, as well as decrease the regulatory burden on industry and on medical practitioners. The bill includes measures which support the introduction of new expedited pathways for the marketing approval of certain medicines and medical devices, by providing a regulation-making power to set out the details of the new pathways for priority review. The detail will be set out in the regulations and will include, for example, the criteria for goods to utilise these pathways, how to apply, what fees may apply et cetera. Such details will be the subject of extensive consultation with industry and other relevant stakeholders before any such regulations are made. Expedited pathways for the registration of certain new medicines are intended to facilitate earlier access for patients with serious and life-threatening conditions who have unmet clinical need. Expedited review processes will also be available for certain medical devices that are identified as novel, such as a device which represents a use of a breakthrough technology and also meets the criteria of addressing an unmet clinical need. The criteria for these pathways are currently being developed in close consultation with consumers, health professionals and industry. Recognising that some important new medicines will be available to patients at an earlier stage, the medicines and medical devices review recommended that the current post-market monitoring framework in Australia be enhanced through a more comprehensive monitoring scheme for medicines and medical devices. The bill supports the implementation of this measure by enhancing compliance requirements for medicines sponsors. The bill supports another review recommendation to allow certain kinds of variations that do not impact the quality, safety or efficacy of medicines to be made through notification. This approach is similar to practices CHAMBER
Thursday, 1 December 2016 HOUSE OF REPRESENTATIVES 19 adopted overseas. The bill provides for regulations to identify what are likely to be low-risk, straightforward changes to product details. The bill also contains measures to support the review recommendation to allow easier access to certain unapproved therapeutic goods by health practitioners through notifying the TGA rather than by requiring preapproval. The bill provides for regulations to be made to allow Australian companies to undertake conformity assessments of the manufacture of medical devices in Australia, rather than the TGA or overseas-based assessment bodies being the only ones able to do such assessments. The precise nature of these details will be the subject of extensive stakeholder consultation before any regulations are made. The bill also provides for regulations to prescribe time periods within which decisions in relation to listed complementary medicines must be made. These timeframes would be the subject of industry consultation before being implemented in regulations. This change removes a barrier to bringing innovative products to market—statutory timeframes provide a degree of certainty and allow sponsors to plan for the rollout of a new listed product containing the new ingredient. The bill provides review and appeal rights for sponsors seeking approval for the use of a new ingredient in listed medicines. The bill includes measures to support the intent of other review recommendations in relation to consolidating TGA advisory committees. A number of minor amendments in the bill aim principally to achieve greater consistency between the regulation of different types of therapeutic goods and to reduce health risks to the public. I commend the bill to the House. Debate adjourned. VET Student Loans (Charges) Bill 2016 Returned from Senate Message received from the Senate returning the bill without amendments or requests. VET Student Loans Bill 2016 Consideration of Senate Message Bill returned from the Senate with amendments. Ordered that the amendments be considered immediately. Senate’s amendments— SCHEDULE A Schedule of the requests by the Senate for amendments (1) Opp (1) [Sheet 7962] Clause 8, page 9 (line 10), before "The amount", insert "(1)". (2) Opp (2) [Sheet 7962] Clause 8, page 9 (after line 17), at the end of clause 8, add: (2) However, if the loan amount is for an approved course provided by a body mentioned in subsection 16(1A) before 1 January 2019, the amount of the loan must not be greater than any of the following: (a) the amount that would reduce the student's FEE-HELP balance to zero; (b) the tuition fees for the course. (3) Opp (3) [Sheet 7962] Clause 13, page 12 (lines 2 to 4), omit the clause, substitute: 13 Approved courses (1) To be an approved course, the course must meet the requirements of this Division or be a course covered by subsection (2). (2) A course is covered by this subsection if: (a) the course was provided on 1 January 2017 by one of the following bodies (taken to be approved course providers under the VET Student Loans (Consequential Amendments and Transitional Provisions) Act 2016): (i) a body established to provide vocational education or training under one of the following: (A) the Technical and Further Education Commission Act 1990 (NSW); (B) the Education and Training Reform Act 2006 (Vic.); (C) the TAFE Queensland Act 2013 (Qld); CHAMBER
Page 1 and 2: COMMONWEALTH OF AUSTRALIA House of
Page 3 and 4: FORTY-FIFTH PARLIAMENT FIRST SESSIO
Page 5 and 6: Members of the House of Representat
Page 7 and 8: Members of the House of Representat
Page 9 and 10: Title (Leader of the House) Ministe
Page 11 and 12: Title Shadow Minister for Disabilit
Page 13 and 14: CONTENTS THURSDAY, 1 DECEMBER 2016
Page 15 and 16: CONTENTS—continued QUESTIONS WITH
Page 17: CONTENTS—continued Women's Safety
Page 20 and 21: 2 HOUSE OF REPRESENTATIVES Thursday
Page 28 and 29: 10 HOUSE OF REPRESENTATIVES Thursda
Page 86 and 87:
68 HOUSE OF REPRESENTATIVES Thursda
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
100 HOUSE OF REPRESENTATIVES Thursd
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
show all

House of Representatives

Create successful ePaper yourself

Delete template?

Save as template?